Cetuximab (Cmab), a monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), appears to be associated with tumor growth inhibition and is one of the few targeted therapies currently used [10-12]. The gene discussed is EGFR; the disease is neoplasm.